ALKERMES INC
SpecialtyALKERMES INC is a specialty pharmaceutical company focused on Respiratory, Gastroenterology. Key products include LYBALVI.
ALKERMES INC at a Glance
- Fast trial execution (13 months median completion)
ALKERMES INC's Key Drugs
ALKERMES INC's core commercial portfolio centers on LYBALVI, ARISTADA, ARISTADA INITIO KIT, spanning Respiratory and Gastroenterology — its most strategically important drugs approved in the last 15 years.
ALKERMES INC's Recent FDA Approvals
New NDA/BLA approvals for ALKERMES INC over the last two years — novel drugs only, excluding generics and label supplements.
ALKERMES INC's Therapeutic Areas
ALKERMES INC's approved drugs and pipeline span 2 therapeutic areas, led by Respiratory and Gastroenterology, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ALKERMES INC's Top Competitors
ALKERMES INC's closest competitors by therapeutic-area and drug-target overlap include APOTHECON, MALLINCKRODT, and LEGACY PHARMA. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ALKERMES INC Pipeline Snapshot
ALKERMES INC has 2 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 1 Phase 1.
Phase 3 Readout Calendar Pro
6 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 20/27 completed
- • Speed: 13 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (3)
Discontinued (0)
Company Info
- First Approval
- 2006-04-13
- Latest
- 2026-01-30
- Applications
- 4
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges